ReviewEJIFCC2026
Triglyceride - Glucose (TyG) Index as a Screening Tool in Community Settings for Early Detection of Type 2 Diabetes Risk: A Systematic Review.
Review in EJIFCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Association of baseline and cumulative CHG index with risk of new-onset sarcopenia in middle-aged and older adults.The journal of nutrition, health & aging · 2026Article
- Machine learning-based diagnostic models for prevalent metabolic syndrome among patients with disuse muscle atrophy: a comparative study of seven algorithms.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 Diabetes Mellitus (T2DM) prevalence is rising globally, especially in low- and middle-income countries, and many cases remain undiagnosed until complications occur. Early identification in community settings is crucial. The Triglyceride-Glucose (TyG) index has been proposed as a simple and low-cost surrogate marker of insulin resistance. Objective: This systematic review aims to evaluate the performance and applicability of the TyG index as a community-based screening tool for identifying individuals at risk of T2DM in young and adult populations. Methods: We conducted a systematic literature search in PubMed, Scopus, Web of Science, and Medline (2015-2025). Observational studies in community or primary care populations were included if they reported TyG cutoff and diagnostic accuracy metrics. Data extraction covered study design, population, TyG cutoff values, and performance metrics. Study quality was assessed using the QUADAS-2 tool. Results: Seventeen studies conducted across Asia, Latin America, and Europe met the inclusion criteria. TyG cutoff values varied between 4.49-9.45. In nearly all studies, higher TyG values were significantly associated with insulin resistance, impaired fasting glucose, or incident T2DM. The TyG index frequently demonstrated comparable or superior diagnostic performance relative to HOMA-IR in prediction settings. Conclusion: The TyG index is a feasible, reliable, and low-cost biomarker for community-level screening of T2DM risk. For implementation in settings like Indonesia, local validation of cutoff values and cost-effectiveness studies are needed. Implementation of the TyG index in primary-care screening could improve cost-effective detection of metabolic risk in resource-limited settings.
Indexed as
Identifiers
41659288PMC12882067What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.